CD38 and Miyoshi myopathy: Due to the single-arm, phase 2 design of the present study we cannot determine whether extended DaraKRd is preferred over other treatment strategies for transplant-eligible MM, which might include a more abbreviated course of the same regimen followed by less intensive maintenance therapy, an alternative choice of CD38 antibody, PI, or IMiD, and/or the use of consolidative autologous transplant.